Drug intelligence / Profile preview

MAR

Development stage: Phase 2
Lead developer: Noah Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

MAR is a fixed-dose combination polypill developed by Noah Pharmaceuticals, Inc. It is administered as a once-daily tablet and is currently in a Phase 2 clinical study for the treatment of Alzheimer's disease. The study aims to explore and quantify treatment-related changes across multiple clinical outcomes in patients with very mild to severe Alzheimer's Disease.

Beyond the preview

Go deeper on MAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAR.

Explore the full profile